Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Smith & Nephew Snats ( (SNN) ) has issued an update.
On 2 March 2026, Smith & Nephew reported its fourth-quarter and full-year 2025 results, showing a solid uplift in performance as revenue for 2025 rose 6.1% to $6.16 billion, trading profit climbed 15.5% to $1.21 billion, and free cash flow surged 52.5% to $840 million. The company highlighted broad-based growth across all three business units, stronger margins, robust cash generation that supported a $500 million share buyback and a higher dividend, and improved adjusted ROIC despite portfolio rationalisation.
Management declared the company’s 12-Point Plan transformation complete, citing restored orthopaedics performance, acceleration in sports medicine and advanced wound management, and a culture shift toward productivity and accountability. With the new RISE strategy launched in December 2025, new 2028 financial targets, and the completed acquisition of Integrity Orthopaedics, Smith & Nephew signalled an ambition to accelerate revenue growth, trading profit and returns in 2026 and beyond, aiming to expand its leadership in healthcare innovation and deliver sustainable value for shareholders and other stakeholders.
The most recent analyst rating on (SNN) stock is a Hold with a $34.91 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Neutral.
Smith & Nephew Snats’ strong financial performance and positive earnings call are the main drivers of its stock score. However, bearish technical indicators and a high P/E ratio temper the overall outlook. The company’s strategic initiatives, such as the share buyback, reflect confidence in its financial health, but challenges in emerging markets and tariff impacts pose risks.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew is a global medical technology company listed in London and New York, focused on orthopaedics, sports medicine and ear, nose and throat (ENT) devices, and advanced wound management products. The group targets hospital and ambulatory care providers worldwide, positioning itself as a leader in surgical innovation and wound care solutions with a growing emphasis on sports medicine.
Average Trading Volume: 784,554
Technical Sentiment Signal: Buy
Current Market Cap: $15.66B
See more data about SNN stock on TipRanks’ Stock Analysis page.